N=32

Age, Mean ± SD

62.7 ± 4.15

SEX: N(%):

F

6 (18.8%)

M

26(81.2%)

Smoking, N (%):

No

18 (56.2%)

Yes

14 (43.8%)

Family History, N (%):

NO

30 (93.8%)

Unknown

2 (6.25%)

Comorbid Disease, N (%):

COPD

1 (3.12%)

DM

3 (9.38%)

HTN

6 (18.8%)

HTN, COPD

1 (3.12%)

HTN, DM

6 (18.8%)

HTN, DM, IHD

1 (3.12%)

HTN, IHD

2 (6.25%)

No

12 (37.5%)

Pathological Type, N (%):

Chromophobe

1 (3.12%)

Clear cell

27 (84.4%)

Medullary

1 (3.12%)

Papillary

3 (9.38%)

Stage at Presentation, N (%)

1

5 (15.6%)

2

7 (21.9%)

3

13 (40.6%)

4

7 (21.9%)

Performance Status, N (%)

1

16 (50.0%)

2

14 (43.8%)

3

12 (6.25%)

Treatment received, N (%):

afinitor

5 (15.6%)

sutent

11 (34.4%)

votrient

16 (50.0%)

baseline NLR, Mean±SD

3.17±1.07

Difference NLR (baseline and after 2 m), Mean±SD

2.70±1.23

after 2 mon NLR, Mean±SD

5.88±2.06

number of metastatic sites, N (%):

1

20 (62.5%)

2

11 (34.4%)

3

1 (3.12%)

organs, N (%):

Locoregional

1 (3.12%)

liver

6 (18.8%)

liver and bone

1 (3.12%)

liver and local

1 (3.12%)

bone and locoregional

1 (3.12%)

lung

13 (40.6%)

lung and bone

1 (3.12%)

lung and brain

1 (3.12%)

lung and liver

5 (15.6%)

lung and liver and bone

1 (3.12%)

lung and local

1 (3.12%)

response to treatment after 2 months, N (%):

PR

19 (59.4%)

progress

6 (18.8%)

SD

7 (21.9%)

Response, N (%):

Not progressed

26 (81.2%)

Progressed

6 (18.8%)

Survival, N (%):

Alive

2 (6.25%)

Dead

30 (93.8%)